Abivax: Third Quarter 2025 Financial Results

Abivax, a biotechnology company, has released its financial results for the third quarter of 2025. Available cash stands at €589.7 million, ensuring financial stability until the end of 2027. The operating loss increased by €44.2 million, reaching €174.4 million. This increase primarily reflects higher research and development expenses, which climbed to €133.4 million, driven by programs for ulcerative colitis and Crohn's disease. Conversely, sales and marketing expenses decreased by €1.7 million. General expenses increased due to social charges related to the rise in the share price. Finally, the net financial position improved significantly, reaching €543.3 million.